{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:39Z","timestamp":1787020839727,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Delta-9-tetrahydrocannabinol (\u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC) is known to produce systemic analgesia that involves CB\n                    <jats:sub>1<\/jats:sub>\n                    and CB\n                    <jats:sub>2<\/jats:sub>\n                    cannabinoid receptors. However, there is compelling evidence that \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC can potently inhibit Cav3.2T-type calcium channels which are highly expressed in dorsal root ganglion neurons and in the dorsal horn of the spinal cord. Here, we investigated whether spinal analgesia produced by \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC involves Cav3.2 channels vis a vis cannabinoid receptors. We show that spinally delivered \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC produced dose-dependent and long-lasting mechanical anti-hyperalgesia in neuropathic mice, and showed potent analgesic effects in models of inflammatory pain induced by formalin or Complete Freund\u2019s Adjuvant (CFA) injection into the hind paw, with the latter showing no overt sex differences. The \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC mediated reversal of thermal hyperalgesia in the CFA model was abolished in Cav3.2 null mice, but was unaltered in CB\n                    <jats:sub>1<\/jats:sub>\n                    and CB\n                    <jats:sub>2<\/jats:sub>\n                    null animals. Hence, the analgesic effects of spinally delivered \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC are due to an action on T-type calcium channels, rather than activation of spinal cannabinoid receptors.\n                  <\/jats:p>","DOI":"10.1186\/s13041-023-01036-8","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T07:01:57Z","timestamp":1684998117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Analgesia by intrathecal delta-9-tetrahydrocannabinol is dependent on Cav3.2 calcium channels"],"prefix":"10.1186","volume":"16","author":[{"given":"Vinicius de Maria","family":"Gadotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Tasmin Techera","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0644-9066","authenticated-orcid":false,"given":"Gerald W.","family":"Zamponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"1036_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13041-022-00923-w","volume":"15","author":"EK Harding","year":"2022","unstructured":"Harding EK, Zamponi GW. Central and peripheral contributions of T-type calcium channels in pain. Mol Brain. 2022;15:39.","journal-title":"Mol Brain"},{"key":"1036_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/sj.emboj.7600515","volume":"24","author":"E Bourinet","year":"2005","unstructured":"Bourinet E, Alloui A, Monteil A, Barr\u00e8re C, Couette B, Poirot O, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. 2005;24:315\u201324.","journal-title":"EMBO J"},{"key":"1036_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.celrep.2014.12.042","volume":"10","author":"A Fran\u00e7ois","year":"2015","unstructured":"Fran\u00e7ois A, Sch\u00fcetter N, Laffray S, Sanguesa J, Pizzoccaro A, Dubel S, et al. The low-threshold calcium channel Cav3.2 determines low-threshold mechanoreceptor function. Cell Rep. 2015;10:370\u201382.","journal-title":"Cell Rep"},{"key":"1036_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/bph.13906","volume":"175","author":"T Snutch","year":"2018","unstructured":"Snutch T, Zamponi GW. Recent advances in the development of T-type calcium channel blockers for pain intervention. Br J Pharmacol. 2018;175:2375\u201383.","journal-title":"Br J Pharmacol"},{"key":"1036_CR5","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1093\/emboj\/20.24.7033","volume":"20","author":"J Chemin","year":"2001","unstructured":"Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 2001;20:7033\u201340.","journal-title":"EMBO J"},{"key":"1036_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13041-021-00876-6","volume":"14","author":"VM Gadotti","year":"2021","unstructured":"Gadotti VM, Huang S, Zamponi GW. The terpenes camphene and alpha-bisabolol inhibit inflammatory and neuropathic pain via Cav3.2 T-type calcium channels. Mol Brain. 2021;14:166.","journal-title":"Mol Brain"},{"key":"1036_CR7","doi-asserted-by":"publisher","first-page":"16124","DOI":"10.1074\/jbc.M707104200","volume":"283","author":"HR Ross","year":"2008","unstructured":"Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem. 2008;283:16124\u201334.","journal-title":"J Biol Chem"},{"key":"1036_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16035","author":"EK Harding","year":"2023","unstructured":"Harding EK, Souza IA, Gandini MA, Gadotti VM, Ali MY, Huang S, et al. Differential regulation of Cav 3.2 and Cav 2.2 calcium channels by CB1 receptors and cannabidiol. Br J Pharmacol. 2023. https:\/\/doi.org\/10.1111\/bph.16035.","journal-title":"Br J Pharmacol"},{"issue":"15","key":"1036_CR9","doi-asserted-by":"publisher","first-page":"8649","DOI":"10.3390\/ijms23158649","volume":"23","author":"SL Casey","year":"2022","unstructured":"Casey SL, Mitchell VA, Sokolaj EE, Winters BL, Vaughan CW. Intrathecal actions of the cannabis constituents \u0394(9)-Tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model. Int J Mol Sci. 2022;23(15):8649.","journal-title":"Int J Mol Sci"},{"key":"1036_CR10","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1111\/bph.14958","volume":"177","author":"XF Wang","year":"2020","unstructured":"Wang XF, Galaj E, Bi GH, Zhang C, He Y, Zhan J, et al. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1 \/CB2 versus GPR55 receptors. Br J Pharmacol. 2020;177:1865\u201380.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"1036_CR11","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.neuron.2014.07.036","volume":"83","author":"A Garc\u00eda-Caballero","year":"2014","unstructured":"Garc\u00eda-Caballero A, Gadotti VM, Stemkowski P, Weiss N, Souza IA, Hodgkinson V, et al. The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. Neuron. 2014;83(5):1144\u201358.","journal-title":"Neuron"},{"key":"1036_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin. Brit J Pharmacol. 2008;153:199\u2013215.","journal-title":"Brit J Pharmacol"},{"key":"1036_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5055\/jom.2009.0034","volume":"5","author":"J Elikottil","year":"2009","unstructured":"Elikottil J, Guopota P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5:341\u201357.","journal-title":"J Opioid Manag"},{"key":"1036_CR14","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1073\/pnas.96.10.5780","volume":"96","author":"A Zimmer","year":"1999","unstructured":"Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96:5780\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1036_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1744-8069-9-32","volume":"9","author":"VM Gadotti","year":"2013","unstructured":"Gadotti VM, You H, Petrov RR, Berger ND, Diaz P, Zamponi GW. Analgesic effect of a mixed T-type channel inhibitor\/CB2 receptor agonist. Mol Pain. 2013;9:32.","journal-title":"Mol Pain"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-023-01036-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T11:07:35Z","timestamp":1688987255000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-023-01036-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1186\/s13041-023-01036-8","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A given name of the author Vinicius de Maria Gadotti was incorrectly indicated in the HTML version as family name in the original publication, this article has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Calgary\u2019s ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}